BAM
LAB icon

Blueshift Asset Management’s Standard BioTools LAB Stock Holding History

Blueshift Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-33,827
Closed -$203K – 970
2020
Q4 		$203K Buy
+33,827
New +$222K 0.02% 622

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Blueshift Asset Management's LAB Position: Q1 2021 in Review

Blueshift Asset Management sold out of Standard BioTools (LAB) in Q1 2021, closing a stake of 33,827 shares — an estimated $203K sold.

Blueshift Asset Management first reported a position in LAB in Q4 2020 and held it in 1 quarter. The position peaked at $203K in Q4 2020. 138 funds tracked by Wall St. Rank hold LAB as of Q1 2021.

  • Blueshift Asset Management reported no remaining Standard BioTools position as of Q1 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 33,827 Standard BioTools shares in Q1 2021, an estimated $203K.
  • Blueshift Asset Management first reported a position in Standard BioTools in Q4 2020 and held it in 1 quarter.
  • Blueshift Asset Management's Standard BioTools position peaked at $203K in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2021.

Based on Blueshift Asset Management's 13F filing for Q1 2021, filed 6 May 2021.